Ignite Creation Date:
2025-12-25 @ 1:34 AM
Ignite Modification Date:
2026-04-11 @ 8:18 AM
Study NCT ID:
NCT06750094
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2024-12-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Sponsor:
Janssen Research & Development, LLC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
61186372COR3002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None